Latest headlines

Novo Nordisk A/S News

Q: Why is Novo Nordisk A/S up or down today?

Novo Nordisk A/S (NVO) moves on news. The headlines above show what is driving NVO today; cross-check the reaction against its Fear and Greed Index and trading volume.

Q: How often is Novo Nordisk A/S news updated?

The Novo Nordisk A/S (NVO) news feed refreshes continuously as new stories are published.

Q: How does Novo Nordisk A/S news relate to its Fear and Greed Index?

News drives sentiment and sentiment drives price. Read Novo Nordisk A/S news alongside its Fear and Greed Index to separate noise from a real shift in mood.

The latest Novo Nordisk A/S (NVO) news, aggregated as it breaks. News moves sentiment and sentiment moves price, so read these NVO headlines next to the live Novo Nordisk A/S Fear and Greed Index.

Latest Novo Nordisk A/S Headlines54

Novo Nordisk: The Pill That Could Close The Gap With Lilly

seekingalpha.com · Aug 21, 2026

Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?

zacks.com · Aug 20, 2026

Celon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump

reuters.com · Aug 20, 2026

Novo Nordisk: The Best Value In Pharma

seekingalpha.com · Aug 19, 2026

Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills

wsj.com · Aug 19, 2026

Eli Lilly, Novo Nordisk Battle It Out In Weight-Loss Pills Market

investors.com · Aug 19, 2026

Novo begins study to find lowest effective dose for Wegovy pill

reuters.com · Aug 19, 2026

3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now

fool.com · Aug 18, 2026

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

zacks.com · Aug 17, 2026

NVO DCF Analysis: Intrinsic Value $91 vs Price $46

gurufocus.com · Aug 17, 2026

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?

fool.com · Aug 13, 2026

Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?

zacks.com · Aug 13, 2026

Novo CEO says obesity market won't be winner-take-all battle with Lilly

reuters.com · Aug 13, 2026

Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer

youtube.com · Aug 12, 2026

Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'

cnbc.com · Aug 12, 2026

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

gurufocus.com · Aug 12, 2026

Novo Nordisk CEO sees ‘long runway' for weight-loss drugs as obesity grips America

foxbusiness.com · Aug 12, 2026

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

zacks.com · Aug 12, 2026

PHARMA BETS: CEO turns to AI for next-generation drugs

youtube.com · Aug 12, 2026

The Market Is (Still) Underestimating Novo Nordisk

seekingalpha.com · Aug 12, 2026

Novo Nordisk Stock: Buy or Sell?

fool.com · Aug 11, 2026

Better Buy: Eli Lilly vs. Novo Nordisk

fool.com · Aug 11, 2026

Novo Nordisk A/S Q2 Earnings Call Highlights

marketbeat.com · Aug 8, 2026

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

fool.com · Aug 7, 2026

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

gurufocus.com · Aug 7, 2026

Novo Nordisk: Dismal Q2 Earnings, Operational Frailties Warrant Rating Downgrade

seekingalpha.com · Aug 7, 2026

Why Is Everyone Talking About Novo Nordisk?

fool.com · Aug 6, 2026

Novo Nordisk: The Market Has Lost Its Mind, Too Cheap To Ignore

seekingalpha.com · Aug 6, 2026

NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift

zacks.com · Aug 6, 2026

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

cnbc.com · Aug 6, 2026

Novo Nordisk Stock Falls 4% Despite Stronger GLP-1 Outlook

gurufocus.com · Aug 5, 2026

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

marketwatch.com · Aug 5, 2026

NVO Stock Down Despite Q2 Earnings and Sales Beat on GLP-1 Growth

zacks.com · Aug 5, 2026

Novo Nordisk: Opportunistically Adding To A Long-Term Winner (Q2 Review)

seekingalpha.com · Aug 5, 2026

Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case

reuters.com · Aug 5, 2026

FTSE 100 Live: Gold miners provide boost, but Pru and HSBC hit by China tax report

proactiveinvestors.com · Aug 5, 2026

Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative Deals

wsj.com · Aug 5, 2026

FTSE 100 Live: Next and Glencore provide results boost, SpaceX tumbles

proactiveinvestors.com · Aug 5, 2026

Novo Nordisk CEO addresses investors' high Wegovy pill expectations

youtube.com · Aug 5, 2026

Novo Nordisk's raised forecast fails to change the debate over its obesity business

cnbc.com · Aug 5, 2026

Novo CEO faces investor grilling after outlook hike soured by pipeline concerns

reuters.com · Aug 5, 2026

The Wegovy pill's ‘surprise miss' is one reason Novo Nordisk's stock is down

marketwatch.com · Aug 4, 2026

Novo Nordisk stock falls despite outlook hike as Wegovy sales miss hopes

invezz.com · Aug 4, 2026

Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks

benzinga.com · Aug 4, 2026

Novo Nordisk Raises Earnings Guidance. The Stock Sinks.

barrons.com · Aug 4, 2026

Novo Nordisk shares slide after guidance disappoints investors

cnbc.com · Aug 4, 2026

Wegovy Maker Novo Nordisk Lifts Guidance After Second-Quarter Boost

wsj.com · Aug 4, 2026

Novo Nordisk's Q2 profit beats forecasts, raises outlook

reuters.com · Aug 4, 2026

Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?

zacks.com · Aug 3, 2026

Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines

proactiveinvestors.com · Aug 3, 2026

Citi says Novo selloff overdone but GLP-1 worries keep it on the sidelines

proactiveinvestors.co.uk · Aug 3, 2026

5 Things to Know Before the Stock Market Opens on Monday

investopedia.com · Aug 3, 2026

Obesity battle heats up again as Novo claws way back into race with Lilly

reuters.com · Aug 3, 2026

Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip?

fool.com · Jul 31, 2026

Why Is Novo Nordisk A/S Up or Down Today?

When Novo Nordisk A/S (NVO) moves sharply, the reason is almost always in the headlines above. Earnings, guidance, analyst upgrades and downgrades, product news and macro data are the usual drivers of a NVO move on the day. The feed shows what broke and when, and the sentiment tag on each story shows whether the coverage skews positive or negative, so you can see at a glance why Novo Nordisk A/S is up or down today.

How Novo Nordisk A/S News Affects the Price

News does not move the Novo Nordisk A/S (NVO) price directly, it moves sentiment, and sentiment moves price. A run of negative headlines pulls the Novo Nordisk A/S Fear and Greed Index toward fear, while positive coverage pushes it toward greed, often before the price has fully reacted. A surprise story usually shows up first as a spike in Novo Nordisk A/S trading volume. That is the chain to watch: headline, sentiment, volume, then the NVO price.

Trade the Novo Nordisk A/S News With Sentiment

Headlines tell you what happened; the Fear and Greed Index tells you how the crowd is reacting. Watch Novo Nordisk A/S trading volume spike on a big story, check the Novo Nordisk A/S price history for context, follow the live NVO price, see the Novo Nordisk A/S price prediction, and read the Novo Nordisk A/S Fear and Greed Index for mood.

How do you feel about Novo Nordisk A/S?

Frequently asked questions

Why is Novo Nordisk A/S up or down today?

Novo Nordisk A/S (NVO) moves on news, and the headlines above are the fastest way to see what is driving NVO today, from earnings, guidance and analyst moves to the broader market mood. Cross-check the reaction against the live Novo Nordisk A/S Fear and Greed Index and NVO trading volume.

What is the latest Novo Nordisk A/S news?

The newest Novo Nordisk A/S (NVO) headlines are listed above, most recent first, each linking to the original source. We pull the last 60 stories so you can scroll the full recent NVO news cycle in one place.

Where does Novo Nordisk A/S news come from?

We aggregate Novo Nordisk A/S (NVO) headlines from financial news wires and refresh them continuously. Each headline links straight to the original source.

How often is Novo Nordisk A/S news updated?

Continuously. The Novo Nordisk A/S (NVO) feed refreshes as new stories are published, so the headlines at the top are the freshest available.

How does Novo Nordisk A/S news relate to its Fear and Greed Index?

News drives sentiment, and sentiment drives price. A run of negative headlines tends to push the Novo Nordisk A/S Fear and Greed Index toward fear, positive coverage toward greed. Reading them together is how you separate noise from a real shift in mood.

Headlines are aggregated from third-party sources and link to the original publishers. CFGI does not author or endorse them.

About CFGI

The per-asset sentiment record.

CFGI is a market sentiment data company that scores crowd emotion from 0 to 100 across crypto and stock markets. Crypto readings cover the whole market and hundreds of individual assets across 15-minute, 1-hour, 4-hour and daily views. The stock index gives a live daily reading for wider stock market sentiment.

Every CFGI score is built from 10 indicators: price, volatility, volume, impulse, technical analysis, social media, dominance, search interest, whale movements and order book pressure. The same data powers our API, alerts and embeddable widgets.